Nab-Paclitaxel Improves PFS in Treatment-Naïve Metastatic Malignant Melanoma

Share this content:
(ChemotherapyAdvisor) – Nab-paclitaxel significantly improved progression-free survival (PFS), the primary end point, when compared with dacarbazine in treatment-naïve patients with metastatic malignant melanoma, investigators reported during the Society for Melanoma Research 2012 Congress, held in Hollywood, CA.

A trend was also observed with nab-paclitaxel vs dacarbazine toward improved overall survival (OS), Evan M. Hersh, MD, of the Arizona Cancer Center, Tucson, AZ, USA, and colleagues noted.

The global phase 3 open-label trial enrolled 529 patients with stage IV metastatic malignant melanoma with no brain metastasis, who were randomly assigned to receive nab-paclitaxel 150 mg/m2 on days 1, 8, and 15 every 4 weeks (n=264) or dacarbazine 1000 mg/m2 every 3 weeks (n=265) between April 2009 and June 2011.

Baseline patient characteristics were well balanced; the majority were male (66%), had an ECOG status of 0 (71%), and had M1c stage disease (65%).

In the intent-to-treat population, median PFS, based on blinded assessment of CT scans obtained every 8 weeks and evaluated per RECIST, was 4.8 months in the nab-paclitaxel arm and 2.5 months in the dacarbazine arm (HR 0.792; 95.1% CI 0.631–0.992; P=0.044).

Interim OS, conducted at the time of primary PFS analysis, was 12.8 months in the nab-paclitaxel arm and 10.7 months in the dacarbazine arm (HR 0.831; 99.9% CI 0.578–1.196; P=0.094).

“Seventy-three percent patients received subsequent therapies, which were well balanced between the two arms,” Dr. Hersh noted. Objective response rate, independently assessed, was 15% in the nab-paclitaxel arm vs 11% in the dacarbazine arm (P=0.239) and disease-control rate was 39% vs 27% (P=0.004), respectively.

The most common grade 3 or 4 treatment-related adverse events reported in >10% of patients were neuropathy, 25% in the nab-paclitaxel arm vs 0% in the dacarbazine arm (P<0.001), and neutropenia, 20% vs 10%, respectively (P=0.004). Median time to neuropathy improvement was 28 days.

The study was sponsored by Celgene Corp., the manufacturer of nab-paclitaxel (Abraxane).

Abstract (search for Hersh)

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs